Global Stem Cells Group and ReGen Form Strategic Partnership to Advance Regenerative Care Worldwide
Global Stem Cells Group, a leader in the field of regenerative medicine, proudly announces an innovative partnership with ReGen, a highly acclaimed Turkish clinic renowned for its cutting-edge technologies in aesthetic and regenerative care. This strategic alliance exemplifies Global Stem Cells Group’s commitment to advancing the field of regenerative medicine and expanding global access to transformative treatments.
As a trailblazer in the industry, Global Stem Cells Group actively seeks strategic partnerships with companies and organizations that share its vision of advancing regenerative care. The collaboration with ReGen signifies a remarkable milestone in this endeavor.
A Solid Partnership
ReGen, a highly regarded clinic specializing in advanced regenerative care technologies, has joined forces with Global Stem Cells Group to facilitate the expansion of franchising opportunities for specialized regenerative care clinics worldwide. By harnessing the collective strengths of both organizations, this partnership aims to cultivate an environment where their shared expertise and services can flourish, delivering regenerative healthcare solutions to individuals across the globe.
Rapid Growth
Through the partnership, ReGen has experienced remarkable growth, leveraging the Global Stem Cells Group’s name and resources to open two state-of-the-art clinics in Buenos Aires, Argentina, and Cancun, Mexico. These clinics have established themselves as pioneers in the field of regenerative care, surpassing existing alternatives in the region.
By introducing cutting-edge aesthetic treatments such as the perfected hair transplant technique from Turkey, ReGen is revolutionizing the landscape of regenerative healthcare. The clinics now offer patients access to the latest and most effective treatment options available. ReGen’s ability to bring their expertise to new regions underscores Global Stem Cells Group’s vision of making their exceptional services accessible to individuals worldwide.
The Trained Expert Behind ReGen
Leading the way at ReGen is Dr. Salih Yildirim, an esteemed CEO with a visionary mindset committed to spearheading a paradigm shift in the realm of regenerative medicine. Driven by an unwavering passion to extend the benefits of cutting-edge aesthetic technologies hailing from Turkey, encompassing areas such as hair transplantation, rhinoplasty, mammoplasty, and stem cell treatments, he has taken the momentous decision to expand the global presence of ReGen clinics. This strategic alliance with the esteemed Global Stem Cells Group aims to grant greater accessibility to Turkey’s esteemed aesthetic and regenerative medicine treatments, catering to a broader spectrum of patients.
Evident in this initiative is ReGen’s resolute dedication to disseminate its advanced techniques and state-of-the-art technologies across the globe, thereby propelling progress in the field of regenerative medicine.
How Global Stem Cells Group Can Improve ReGen’s Reach
While ReGen brings its advanced techniques and expertise to the partnership, Global Stem Cells Group offers a range of valuable resources. As a conglomerate of companies engaged in product manufacturing and comprehensive training through the International Society for Stem Cell Application (ISSCA), Global Stem Cells Group enhances the partnership’s outreach and impact. This collaboration has the potential to be life-changing for individuals seeking regenerative care worldwide.
Dr. Yildirim expresses his satisfaction with the partnership, stating, “We are delighted to join forces with Global Stem Cells Group. This collaboration allows us to establish additional points of care globally, furthering the accessibility of stem cell applications and advancing regenerative medicine.”
This milestone partnership between Global Stem Cells Group and ReGen is destined to reshape the world of regenerative care. It represents a turning point that will be remembered as a transformative moment for the field of regenerative medicine.
Benito Novas, CEO of Global Stem Cells Group, emphasizes the significance of this alliance, stating, “Our collaboration with Dr. Yildirim spans several years, and he has consistently demonstrated exceptional leadership and humility. By incorporating the ReGen program into the Global Stem Cells Group umbrella, which encompasses products manufacturing, ISSCA training, and centers of excellence for point-of-care regenerative medicine, we continue to solidify our commitment to excellence.”
As this partnership evolves, both organizations will continue to work tirelessly to develop new treatments, enhance existing procedures, and ensure the highest standards of patient care. Through their joint efforts, they will accelerate the adoption of regenerative care practices on a global scale, creating a ripple effect that will benefit patients and healthcare providers alike.
For more information about Global Stem Cells Group and its regenerative medicine solutions, please visit https://www.stemcellsgroup.com/.
About Global Stem Cells Group
Global Stem Cells Group is a leading provider of regenerative medicine solutions, dedicated to advancing healthcare through innovative therapies. With a global presence and a multidisciplinary team of experts, the organization strives to harness the potential of stem cells and regenerative medicine to improve patient outcomes across various medical fields. Through its extensive network of clinics, research facilities, and training centers, Global Stem Cells Group is committed to pushing the boundaries of regenerative medicine and making a positive impact on global healthcare.
About ReGen
ReGen is a highly acclaimed Turkish clinic renowned for its expertise in cutting-edge technologies related to regenerative care. Headquartered in Istanbul, ReGen has gained international recognition for its commitment to excellence and its groundbreaking advancements in regenerative medicine. By partnering with Global Stem Cells Group, ReGen aims to share its advanced techniques and expertise on a global scale, improving access to regenerative care and transforming lives worldwide.
Safe Harbor Statement: Statements in this news release may be “forward-looking statements”. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions, or any other information relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates, and projections about our business based partly on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties, and assumptions that are difficult to predict. Therefore, actual outcomes and results may and are likely to differ materially from what is expressed or forecasted in forward-looking statements due to numerous factors. Any forward-looking statements speak only as of the date of this news release, and The Global Stem Cells Group undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date of this news release. This press release does not constitute a public offer of any securities for sale. Any securities offered privately will not be or have not been registered under the Act and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.
- Published in Press Releases
GSCG Announces the Appointment of Dr. Rafael Moguel as New Chief Medical Officer (CMO) of Cellular Hope Institute Cancun
Global Stem Cells Group (GSCG) has announced the appointment of Dr Rafael Moguel as the new Chief Medical Officer (CMO) of Cellular Hope Institute Cancun.
Dr. Moguel, Fellow of the Society for Cardiac Angiography and Intervention (SCAI), Member of the Mexican Society for Interventional Cardiologists, and Member of the Latin American Society for Interventional Cardiology, comes with a wealth of experience and training.
As CMO with vast knowledge and experience, Dr Moguel is expected to change the direction of Cellular Hope Institute Cancun, which offers patients the best treatments in multiple areas, such as sports medicine, pediatric care, chronic degenerative disease, and autoimmunity. It’s a multi-specialty training center for cellular therapies and regenerative medicine, offering the most advanced treatments in cell therapy.
“I have full confidence in the appointment of Dr Rafael Moguel as the CMO of Cellular Hope Institute Cancun,” said Benito Novas, CEO of Global Stem Cells Group. The CEO also expressed his satisfaction in Dr Moguel’s abilities and experience, and is confident that (Dr Moguel) will advance the objectives of Cellular Hope Institute and propel it to new heights.
With his impressive resume, Dr. Moguel has served in various capacities across several top medical institutions. He was the assistant professor for Cardiology and Interventional Cardiology at Hospital 1° de Octubre, where he also handled hemodynamics and internal medicine.
In his acceptance speech, Dr Moguel said, “I want to affirm and reaffirm my commitment to the goals of Cellular Hope Institute.” With his elaborate working experience and professionalism in cellular therapy, he expressed his confidence in rising to the expectations of Cellular Hope Institute.
Dr. Moguel received his medical degree at Universidad Veracruzana in 1983. He holds a valid certification by the Mexican Cardiology Board for Interventional Cardiology. With more than 10,000 interventional procedures, most notably peripheral and brain intervention, coronary, pacemakers and vein interventions, we believe Dr. Moguel has all it takes to propel Cellular Hope Institute to the next level.
The appointment of Dr. Moguel comes barely two months after an earlier announcement by GSCG about opening the multispecialty regenerative medicine center in Cancun. The facility’s main objective is to incorporate different treatments basing on regenerative medicine, and serve as a training center for cellular therapies and regenerative medicine.
We believe Dr. Moguel’s rich background as an assistant professor and head of interventional cardiology and hemodynamics positions him as the best candidate to run Cellular Hope Institute. His experience is expected to make this facility one of the best cellular therapy centers worldwide, and provide more specialized treatment for patients requiring regenerative medicine.
About Cellular Hope Institute
This facility is a center for both patients and medical experts worldwide, and its main objective is to benefit medical experts and patients globally. The facility achieves this objective through offering the best treatments for patients with multiple conditions, such as spinal cord injury, chronic obstructive pulmonary, sports medicine, and autoimmunity, among others. If you need more information about Cellular Hope Institute, please contact us today.
About the Global Stem Cell Group
Global Stem Cells Group, Inc. is the parent company of six wholly owned operating companies dedicated entirely to stem cell research, training, products, and solutions. Founded in 2012, the company combines dedicated researchers, physician and patient educators, and solution providers with the shared goal of meeting the growing worldwide need for leading edge stem cell treatments and solutions. With a singular focus on this exciting new area of medical research, Global Stem Cells Group and its subsidiaries are uniquely positioned to become global leaders in cellular medicine.
Global Stem Cells Group’s corporate mission is to make the promise of stem cell medicine a reality for patients around the world. With each of GSCG’s six operating companies focused on a separate research-based mission, the result is a global network of state-of-the-art stem cell treatments.
Global Stem Cells Group is a publicly traded company operating under the symbol MSSV. https://finance.yahoo.com/quote/mssv/
To learn more about Global Stem Cells Group, Inc.’s companies visit our website.
- Published in Press Releases
Global Stem Cells Group Subsidiary Adimarket to Launch Progenikine™ SVF Closed System
Global Stem Cells Group subsidiary Adimarket is preparing to launch Progenikine™, a new SVF closed system kit utilizing EmCyte technology, containing all the elements necessary to process adipose tissue and obtain stromal vascular fraction in a sterile environment.
MIAMI, May 31—Adimarket, a subsidiary of Global Stem Cells Group, Inc. is preparing to launch Progenikine™, its new and approved SVF closed system kit using EmCyte technology, and is expected to be available to physicians in July, 2016. The Progenikine kit contains all the elements necessary to process adipose tissue and obtain stromal vascular fraction (SVF) in a closed environment.
Adipose derived stem cells (ASCs) are used by physicians for a variety of indications. Most commonly, ASCs are isolated at the point of care from lipoaspirate (derived from liposuction) tissue as the stromal vascular fraction (SVF), harvested from the patient and immediately administered to the patient as an injection, or used to enrich fat grafts. Isolation of ASCs from adipose tissue is a relatively simple process performed routinely in cell biology laboratories, but isolation at the point of care for immediate clinical administration requires special methodology to prevent contamination, ensure integrity of the clinical procedure, and comply with 
regulatory requirements.
Developed in conjunction with Patrick Pennie, Emcyte CEO, and Maritza Novas Director of Research and Development for Global Stem Cells Group, Progenikine fuses elements from Emcyte systems with the Global Stem cells Group SVF protocols. The kit can provide a low cost, rapid and
simple alternative to traditional methods of isolating ASCs, particularly when smaller quantities are needed.
“We’re excited to launch the Progenikine kit, the newest product designed to help Global Stem Cells Group’s fulfill its m
ission to provide accessible products to our member clients,” says Benito Novas, CEO of Global Stem Cells Group. “These are the milestones that bring us closer to ensuring that more patients will be able to gain access to stem cell therapies.”
To learn more about the Progenikine kit, visit the Global Stem Cells Group website, email bnovas@stemcellsgroup.com, or call 305-560-5337.
About Global Stem Cells Group:
Global Stem Cells Group, Inc. is the parent company of six wholly owned operating companies dedicated entirely to stem cell research, training, products and solutions. Founded in 2012, the company combines dedicated researchers, physician and patient educators and solution providers with the shared goal of meeting the growing worldwide need for leading edge stem cell treatments and solutions.
With a singular focus on this exciting new area of medical research, Global Stem Cells Group and its subsidiaries are uniquely positioned to become global leaders in cellular medicine.
Global Stem Cells Groups corporate mission is to make the promise of stem cell medicine a reality for patients around the world. With each of GSCGs six operating companies focused on a separate research-based mission, the result is a global network of state-of-the-art stem cell treatments.
About Adimarket:
Adimarket, Inc., a division of the Global Stem Cells Group, is a cost-competitive online marketplace for quality regenerative medicine equipment and supplies for physicians and health care professionals.
Adimarket was founded to provide physicians and other health care professionals the tools they need to practice regenerative medicine in a medical office setting. Motivated by a firm belief in the impact the practice of stem cell medicine can have when dispensed in a doctor’s office, Adimarket provides physicians with the tools they need to provide patients with cutting edge treatments.
Adimarket’s experienced customer service representatives provide valuable guidance and advice regarding products relevant to individual practices.
About Emcyte:
Fort Myers, Florida-based EmCyte Corporation is a leader in autologous cellular biologics with the GenesisCS Component Concentrating Systems. These systems provide patients with the best opportunity for rapid recovery an
d provide practitioners with the most advanced clinical point of care experience. EmCyte systems are developed to meet every clinical requirement, giving the physician better clinical choices. EmCyte devices have been independently reviewed and show to produce buffycoat concentrations of 6x to greater than 10x baseline in 7mLs, with yields ranging from 70 percent to greater than 90 percent
EmCyte technology allows for the safe extraction of concentrated platelets and other regenerative cell types from the patient’s own blood. These cells are then re-suspended in a small volume of the patient’s blood plasma and then applied to the treatment site.
To view this release live online, click here
###
- Published in Press Releases
Gordie Howe’s Stem Cells Treatments Support a Growing Appeal for These Therapies Among Athletes and Baby Boomers
The Story of Gordie Howe’s Stem Cell Treatment
In October 2014, Gordie Howe, the legendary hockey player, faced a life-threatening stroke that left him severely debilitated. Despite medical efforts, including an experimental stem cell treatment in Mexico, his condition continued to deteriorate. However, after receiving neural and mesenchymal stem cells, Howe showed remarkable signs of improvement, including regaining mobility and cognitive function.
The Impact of Stem Cell Therapy on Gordie Howe’s Recovery
- Experimental Treatment: Howe’s treatment involved injecting neural and mesenchymal stem cells into his spinal canal, aiming for brain repair and anti-inflammatory benefits.
- Recovery Milestones: Within hours of the procedure, Howe exhibited unexpected improvements, such as walking unaided for the first time since his stroke.
Stem Cell Therapy: Appeal Among Athletes and Baby Boomers
Athletes’ Interest in Stem Cell Therapy
Athletes, prone to injuries and degenerative conditions, increasingly turn to stem cell therapy for its potential regenerative properties. Icons like Bart Starr and John Brodie have also pursued such treatments.
Growing Popularity Among Baby Boomers
The aging population, particularly baby boomers, seeks stem cell therapies to address age-related ailments such as joint degeneration and chronic conditions.
Controversies and Regulatory Challenges
Despite its appeal, stem cell therapy faces scrutiny due to regulatory issues and varying international standards. The FDA is developing guidelines to regulate these treatments, distinguishing between approved clinical trials and unauthorized clinics.
Regulatory Landscape and FDA Guidelines
- Current FDA Oversight: Most stem cell therapies require FDA approval, with exceptions for minimally manipulated cells.
- Unauthorized Clinics: Concerns persist over unauthorized stem cell clinics operating outside regulatory frameworks.
Future Directions and Considerations
As research and public interest in stem cell therapy continue to grow, ongoing debates over efficacy, safety, and regulatory oversight shape its future in medical practice.
- Published in Corporate News / Blog
Stem Cell Treatments Normally Used for Cancer Patients are Helping Multiple Sclerosis Patients
Overview of Stem Cell Transplant for MS Patients
Recent reports from the British Broadcasting Corporation (BBC) highlight the transformative effects of stem cell transplant treatments originally used for cancer patients on individuals suffering from Multiple Sclerosis (MS) in the UK. According to a January 18, 2016 report, this innovative approach has shown promising results in restoring mobility and reversing disability in MS patients.
Autologous Hematopoietic Stem Cell Transplantation (HSCT)
The treatment, known as autologous hematopoietic stem cell transplantation (HSCT), involves the infusion of the patient’s own stem cells harvested from bone marrow. This procedure aims to rebuild the immune system, potentially resetting it to a state before it caused MS-related damage.
Testimonials and Clinical Results
Professors Basil Sharrack and John Snowden from Sheffield’s Royal Hallamshire Hospital emphasize the profound impact of HSCT on MS patients. Patients like Steven Storey, who experienced significant disability progression prior to treatment, have reported remarkable improvements in mobility and quality of life post-transplant.
Steven Storey’s Journey
Steven Storey, diagnosed with MS in 2013, transitioned from being an athlete to wheelchair-bound within a year. Following HSCT, he regained movement in his toes within days and achieved unaided standing after four months. While still using a wheelchair, Storey’s progress is described as astounding, allowing him to swim, cycle, and aspire to walk again.
The MIST International Clinical Trial
The Royal Hallamshire Hospital, alongside institutions in the US, Sweden, and Brazil, participates in the MIST trial. This international study evaluates the long-term benefits of HSCT on patients with relapsing-remitting MS (RRMS), aiming to establish its efficacy as a standard treatment option.
Future Prospects and Research
Prof Richard Burt of Northwestern University leads the MIST trial, pioneering HSCT for MS treatment since 1995. Despite challenges from the pharmaceutical and academic sectors, early studies have shown promising neurological disability reductions, with ongoing research poised to validate these findings further.
Conclusion and Outlook
As ongoing research continues to validate the potential of HSCT in treating MS, stakeholders like Emma Gray, M.D., head of clinical trials at the UK’s MS Society, emphasize its life-changing impacts highlighted by real patient experiences. The outcomes from the MIST trial, expected in 2018, could potentially integrate HSCT into the standard healthcare protocols for MS patients in the UK.
- Published in Corporate News / Blog
